According to a Wall Street Journal report, the preferred Covid-19 shot globally is the Pfizer-BioNTech vaccine.

Bharat Biotech’s intranasal Covid-19 vaccine candidate is expected to enter the Phase II portion of a Phase II/III study within the next few weeks. BBV154 marks the second vaccine against the novel coronavirus developed by the India-based company.